1
|
Benedicto I, Carmona RM, Barettino A, Espinós-Estévez C, Gonzalo P, Nevado RM, de la Fuente-Pérez M, Andrés-Manzano MJ, González-Gómez C, Rolas L, Dorado B, Nourshargh S, Hamczyk MR, Andrés V. Exacerbated atherosclerosis in progeria is prevented by progerin elimination in vascular smooth muscle cells but not endothelial cells. Proc Natl Acad Sci U S A 2024; 121:e2400752121. [PMID: 38648484 PMCID: PMC11066978 DOI: 10.1073/pnas.2400752121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2024] [Accepted: 03/21/2024] [Indexed: 04/25/2024] Open
Abstract
Hutchinson-Gilford progeria syndrome (HGPS) is a rare disease caused by the expression of progerin, a mutant protein that accelerates aging and precipitates death. Given that atherosclerosis complications are the main cause of death in progeria, here, we investigated whether progerin-induced atherosclerosis is prevented in HGPSrev-Cdh5-CreERT2 and HGPSrev-SM22α-Cre mice with progerin suppression in endothelial cells (ECs) and vascular smooth muscle cells (VSMCs), respectively. HGPSrev-Cdh5-CreERT2 mice were undistinguishable from HGPSrev mice with ubiquitous progerin expression, in contrast with the ameliorated progeroid phenotype of HGPSrev-SM22α-Cre mice. To study atherosclerosis, we generated atheroprone mouse models by overexpressing a PCSK9 gain-of-function mutant. While HGPSrev-Cdh5-CreERT2 and HGPSrev mice developed a similar level of excessive atherosclerosis, plaque development in HGPSrev-SM22α-Cre mice was reduced to wild-type levels. Our studies demonstrate that progerin suppression in VSMCs, but not in ECs, prevents exacerbated atherosclerosis in progeroid mice.
Collapse
Affiliation(s)
- Ignacio Benedicto
- Centro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas, Madrid28040, Spain
- Centro Nacional de Investigaciones Cardiovasculares, Madrid28029, Spain
| | - Rosa M. Carmona
- Centro Nacional de Investigaciones Cardiovasculares, Madrid28029, Spain
| | - Ana Barettino
- Centro Nacional de Investigaciones Cardiovasculares, Madrid28029, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares, 28029Madrid, Spain
| | - Carla Espinós-Estévez
- Centro Nacional de Investigaciones Cardiovasculares, Madrid28029, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares, 28029Madrid, Spain
| | - Pilar Gonzalo
- Centro Nacional de Investigaciones Cardiovasculares, Madrid28029, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares, 28029Madrid, Spain
| | - Rosa M. Nevado
- Centro Nacional de Investigaciones Cardiovasculares, Madrid28029, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares, 28029Madrid, Spain
| | | | - María J. Andrés-Manzano
- Centro Nacional de Investigaciones Cardiovasculares, Madrid28029, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares, 28029Madrid, Spain
| | - Cristina González-Gómez
- Centro Nacional de Investigaciones Cardiovasculares, Madrid28029, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares, 28029Madrid, Spain
| | - Loïc Rolas
- Centre for Microvascular Research, William Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, LondonE1 4NS, United Kingdom
| | - Beatriz Dorado
- Centro Nacional de Investigaciones Cardiovasculares, Madrid28029, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares, 28029Madrid, Spain
| | - Sussan Nourshargh
- Centre for Microvascular Research, William Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, LondonE1 4NS, United Kingdom
| | - Magda R. Hamczyk
- Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares, 28029Madrid, Spain
- Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo33006, Spain
| | - Vicente Andrés
- Centro Nacional de Investigaciones Cardiovasculares, Madrid28029, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares, 28029Madrid, Spain
| |
Collapse
|
2
|
Hamczyk MR, Nevado RM. Vascular smooth muscle cell aging: Insights from Hutchinson-Gilford progeria syndrome. Clin Investig Arterioscler 2023; 35:42-51. [PMID: 35125249 DOI: 10.1016/j.arteri.2021.11.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Revised: 10/13/2021] [Accepted: 11/03/2021] [Indexed: 02/08/2023]
Abstract
Vascular smooth muscle cells (VSMCs) constitute the principal cellular component of the medial layer of arteries and are responsible for vessel contraction and relaxation in response to blood flow. Alterations in VSMCs can hinder vascular system function, leading to vascular stiffness, calcification and atherosclerosis, which in turn may result in life-threatening complications. Pathological changes in VSMCs typically correlate with chronological age; however, there are certain conditions and diseases, such as Hutchinson-Gilford progeria syndrome (HGPS), that can accelerate this process, resulting in premature vascular aging. HGPS is a rare genetic disorder characterized by severe VSMC loss, accelerated atherosclerosis and death from myocardial infarction or stroke during the adolescence. Because experiments with mouse models have demonstrated that alterations in VSMCs are responsible for early atherosclerosis in HGPS, studies on this disease can provide insights into the mechanisms of vascular aging and assess the relative contribution of VSMCs to this process.
Collapse
Affiliation(s)
- Magda R Hamczyk
- Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, 33006 Oviedo, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.
| | - Rosa M Nevado
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), 28029 Madrid, Spain
| |
Collapse
|
3
|
Nevado RM, Hamczyk MR, Andrés V. Isolation of Mouse Aortic RNA for Transcriptomics. Methods Mol Biol 2022; 2419:611-627. [PMID: 35237992 DOI: 10.1007/978-1-0716-1924-7_38] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Aging is associated with alterations in the arterial wall that promote vascular disease development and its clinical manifestations, including myocardial infarction, stroke, and arterial dissection. The arterial wall is comprised of three layers, intima, media and adventitia, each with distinct cellular composition and function, which can therefore contribute differently to vascular disease initiation and progression. Hence, studying transcriptomic alterations, either in the entire arterial wall or separately in the three arterial layers, can aid in disentangling the etiopathology of vascular disease and thus pave the way for innovative treatments. This chapter describes protocols for total RNA extraction from complete mouse aorta and separately from intima, media, and adventitia layers for subsequent transcriptomic analysis.
Collapse
Affiliation(s)
- Rosa M Nevado
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
| | - Magda R Hamczyk
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.,Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Oviedo, Spain
| | - Vicente Andrés
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain. .,Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
| |
Collapse
|
4
|
Sánchez-López A, Espinós-Estévez C, González-Gómez C, Gonzalo P, Andrés-Manzano MJ, Fanjul V, Riquelme-Borja R, Hamczyk MR, Macías Á, Del Campo L, Camafeita E, Vázquez J, Barkaway A, Rolas L, Nourshargh S, Dorado B, Benedicto I, Andrés V. Cardiovascular Progerin Suppression and Lamin A Restoration Rescue Hutchinson-Gilford Progeria Syndrome. Circulation 2021; 144:1777-1794. [PMID: 34694158 PMCID: PMC8614561 DOI: 10.1161/circulationaha.121.055313] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND Hutchinson-Gilford progeria syndrome (HGPS) is a rare disorder characterized by premature aging and death mainly because of myocardial infarction, stroke, or heart failure. The disease is provoked by progerin, a variant of lamin A expressed in most differentiated cells. Patients look healthy at birth, and symptoms typically emerge in the first or second year of life. Assessing the reversibility of progerin-induced damage and the relative contribution of specific cell types is critical to determining the potential benefits of late treatment and to developing new therapies. METHODS We used CRISPR-Cas9 technology to generate LmnaHGPSrev/HGPSrev (HGPSrev) mice engineered to ubiquitously express progerin while lacking lamin A and allowing progerin suppression and lamin A restoration in a time- and cell type-specific manner on Cre recombinase activation. We characterized the phenotype of HGPSrev mice and crossed them with Cre transgenic lines to assess the effects of suppressing progerin and restoring lamin A ubiquitously at different disease stages as well as specifically in vascular smooth muscle cells and cardiomyocytes. RESULTS Like patients with HGPS, HGPSrev mice appear healthy at birth and progressively develop HGPS symptoms, including failure to thrive, lipodystrophy, vascular smooth muscle cell loss, vascular fibrosis, electrocardiographic anomalies, and precocious death (median lifespan of 15 months versus 26 months in wild-type controls, P<0.0001). Ubiquitous progerin suppression and lamin A restoration significantly extended lifespan when induced in 6-month-old mildly symptomatic mice and even in severely ill animals aged 13 months, although the benefit was much more pronounced on early intervention (84.5% lifespan extension in mildly symptomatic mice, P<0.0001, and 6.7% in severely ill mice, P<0.01). It is remarkable that major vascular alterations were prevented and lifespan normalized in HGPSrev mice when progerin suppression and lamin A restoration were restricted to vascular smooth muscle cells and cardiomyocytes. CONCLUSIONS HGPSrev mice constitute a new experimental model for advancing knowledge of HGPS. Our findings suggest that it is never too late to treat HGPS, although benefit is much more pronounced when progerin is targeted in mice with mild symptoms. Despite the broad expression pattern of progerin and its deleterious effects in many organs, restricting its suppression to vascular smooth muscle cells and cardiomyocytes is sufficient to prevent vascular disease and normalize lifespan.
Collapse
Affiliation(s)
- Amanda Sánchez-López
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (A.S.-L., C.E.-E., C.G.-G., P.G., M.J.A.-M., V.F., R.R.-B., M.R.H., A.M., L.d.C., E.C., J.V., B.D., I.B., V.A.).,Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain (A.S.-L., C.G.-G., P.G., M.J.A.-M., V.F., M.R.H., A.M., L.d.C., E.C., J.V., B.D., V.A.)
| | - Carla Espinós-Estévez
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (A.S.-L., C.E.-E., C.G.-G., P.G., M.J.A.-M., V.F., R.R.-B., M.R.H., A.M., L.d.C., E.C., J.V., B.D., I.B., V.A.)
| | - Cristina González-Gómez
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (A.S.-L., C.E.-E., C.G.-G., P.G., M.J.A.-M., V.F., R.R.-B., M.R.H., A.M., L.d.C., E.C., J.V., B.D., I.B., V.A.).,Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain (A.S.-L., C.G.-G., P.G., M.J.A.-M., V.F., M.R.H., A.M., L.d.C., E.C., J.V., B.D., V.A.)
| | - Pilar Gonzalo
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (A.S.-L., C.E.-E., C.G.-G., P.G., M.J.A.-M., V.F., R.R.-B., M.R.H., A.M., L.d.C., E.C., J.V., B.D., I.B., V.A.).,Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain (A.S.-L., C.G.-G., P.G., M.J.A.-M., V.F., M.R.H., A.M., L.d.C., E.C., J.V., B.D., V.A.)
| | - María J Andrés-Manzano
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain (A.S.-L., C.G.-G., P.G., M.J.A.-M., V.F., M.R.H., A.M., L.d.C., E.C., J.V., B.D., V.A.)
| | - Víctor Fanjul
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (A.S.-L., C.E.-E., C.G.-G., P.G., M.J.A.-M., V.F., R.R.-B., M.R.H., A.M., L.d.C., E.C., J.V., B.D., I.B., V.A.).,Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain (A.S.-L., C.G.-G., P.G., M.J.A.-M., V.F., M.R.H., A.M., L.d.C., E.C., J.V., B.D., V.A.)
| | - Raquel Riquelme-Borja
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (A.S.-L., C.E.-E., C.G.-G., P.G., M.J.A.-M., V.F., R.R.-B., M.R.H., A.M., L.d.C., E.C., J.V., B.D., I.B., V.A.)
| | - Magda R Hamczyk
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (A.S.-L., C.E.-E., C.G.-G., P.G., M.J.A.-M., V.F., R.R.-B., M.R.H., A.M., L.d.C., E.C., J.V., B.D., I.B., V.A.).,Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain (A.S.-L., C.G.-G., P.G., M.J.A.-M., V.F., M.R.H., A.M., L.d.C., E.C., J.V., B.D., V.A.).,Now with Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología, Universidad de Oviedo, Spain (M.R.H.)
| | - Álvaro Macías
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (A.S.-L., C.E.-E., C.G.-G., P.G., M.J.A.-M., V.F., R.R.-B., M.R.H., A.M., L.d.C., E.C., J.V., B.D., I.B., V.A.).,Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain (A.S.-L., C.G.-G., P.G., M.J.A.-M., V.F., M.R.H., A.M., L.d.C., E.C., J.V., B.D., V.A.)
| | - Lara Del Campo
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (A.S.-L., C.E.-E., C.G.-G., P.G., M.J.A.-M., V.F., R.R.-B., M.R.H., A.M., L.d.C., E.C., J.V., B.D., I.B., V.A.).,Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain (A.S.-L., C.G.-G., P.G., M.J.A.-M., V.F., M.R.H., A.M., L.d.C., E.C., J.V., B.D., V.A.).,Now with Departamento de Biología Celular, Facultad de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain (L.d.C.)
| | - Emilio Camafeita
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (A.S.-L., C.E.-E., C.G.-G., P.G., M.J.A.-M., V.F., R.R.-B., M.R.H., A.M., L.d.C., E.C., J.V., B.D., I.B., V.A.).,Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain (A.S.-L., C.G.-G., P.G., M.J.A.-M., V.F., M.R.H., A.M., L.d.C., E.C., J.V., B.D., V.A.)
| | - Jesús Vázquez
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (A.S.-L., C.E.-E., C.G.-G., P.G., M.J.A.-M., V.F., R.R.-B., M.R.H., A.M., L.d.C., E.C., J.V., B.D., I.B., V.A.).,Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain (A.S.-L., C.G.-G., P.G., M.J.A.-M., V.F., M.R.H., A.M., L.d.C., E.C., J.V., B.D., V.A.)
| | - Anna Barkaway
- Centre for Microvascular Research, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom (A.B., L.R., S.N.)
| | - Loïc Rolas
- Centre for Microvascular Research, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom (A.B., L.R., S.N.)
| | - Sussan Nourshargh
- Centre for Microvascular Research, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom (A.B., L.R., S.N.)
| | - Beatriz Dorado
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (A.S.-L., C.E.-E., C.G.-G., P.G., M.J.A.-M., V.F., R.R.-B., M.R.H., A.M., L.d.C., E.C., J.V., B.D., I.B., V.A.).,Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain (A.S.-L., C.G.-G., P.G., M.J.A.-M., V.F., M.R.H., A.M., L.d.C., E.C., J.V., B.D., V.A.)
| | - Ignacio Benedicto
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (A.S.-L., C.E.-E., C.G.-G., P.G., M.J.A.-M., V.F., R.R.-B., M.R.H., A.M., L.d.C., E.C., J.V., B.D., I.B., V.A.)
| | - Vicente Andrés
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain (A.S.-L., C.G.-G., P.G., M.J.A.-M., V.F., M.R.H., A.M., L.d.C., E.C., J.V., B.D., V.A.)
| |
Collapse
|
5
|
Hamczyk MR, Nevado RM, Barettino A, Fuster V, Andrés V. Biological Versus Chronological Aging: JACC Focus Seminar. J Am Coll Cardiol 2020; 75:919-930. [PMID: 32130928 DOI: 10.1016/j.jacc.2019.11.062] [Citation(s) in RCA: 163] [Impact Index Per Article: 40.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/30/2019] [Revised: 11/21/2019] [Accepted: 11/25/2019] [Indexed: 01/13/2023]
Abstract
Aging is the main risk factor for vascular disease and ensuing cardiovascular and cerebrovascular events, the leading causes of death worldwide. In a progressively aging population, it is essential to develop early-life biomarkers that efficiently identify individuals who are at high risk of developing accelerated vascular damage, with the ultimate goal of improving primary prevention and reducing the health care and socioeconomic impact of age-related cardiovascular disease. Studies in experimental models and humans have identified 9 highly interconnected hallmark processes driving mammalian aging. However, strategies to extend health span and life span require understanding of interindividual differences in age-dependent functional decline, known as biological aging. This review summarizes the current knowledge on biological age biomarkers, factors influencing biological aging, and antiaging interventions, with a focus on vascular aspects of the aging process and its cardiovascular disease related manifestations.
Collapse
Affiliation(s)
- Magda R Hamczyk
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain; Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Oviedo, Spain. https://twitter.com/HamczykMagda
| | - Rosa M Nevado
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain
| | - Ana Barettino
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain
| | - Valentín Fuster
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Spain; The Zena and Michael A. Wiener Cardiovascular Institute/Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, Mount Sinai School of Medicine, New York, New York
| | - Vicente Andrés
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain.
| |
Collapse
|
6
|
Nevado RM, Hamczyk MR, Gonzalo P, Andrés-Manzano MJ, Andrés V. Premature Vascular Aging with Features of Plaque Vulnerability in an Atheroprone Mouse Model of Hutchinson-Gilford Progeria Syndrome with Ldlr Deficiency. Cells 2020; 9:cells9102252. [PMID: 33049978 PMCID: PMC7601818 DOI: 10.3390/cells9102252] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2020] [Revised: 09/27/2020] [Accepted: 10/04/2020] [Indexed: 12/21/2022] Open
Abstract
Hutchinson–Gilford progeria syndrome (HGPS) is among the most devastating of the laminopathies, rare genetic diseases caused by mutations in genes encoding nuclear lamina proteins. HGPS patients age prematurely and die in adolescence, typically of atherosclerosis-associated complications. The mechanisms of HGPS-related atherosclerosis are not fully understood due to the scarcity of patient-derived samples and the availability of only one atheroprone mouse model of the disease. Here, we generated a new atherosusceptible model of HGPS by crossing progeroid LmnaG609G/G609G mice, which carry a disease-causing mutation in the Lmna gene, with Ldlr−/− mice, a commonly used preclinical atherosclerosis model. Ldlr−/−LmnaG609G/G609G mice aged prematurely and had reduced body weight and survival. Compared with control mice, Ldlr−/−LmnaG609G/G609G mouse aortas showed a higher atherosclerosis burden and structural abnormalities typical of HGPS patients, including vascular smooth muscle cell depletion in the media, adventitial thickening, and elastin structure alterations. Atheromas of Ldlr−/−LmnaG609G/G609G mice had features of unstable plaques, including the presence of erythrocytes and iron deposits and reduced smooth muscle cell and collagen content. Ldlr−/−LmnaG609G/G609G mice faithfully recapitulate vascular features found in patients and thus provide a new tool for studying the mechanisms of HGPS-related atherosclerosis and for testing therapies.
Collapse
MESH Headings
- Aging, Premature/metabolism
- Aging, Premature/physiopathology
- Animals
- Aorta/metabolism
- Atherosclerosis/metabolism
- Atherosclerosis/physiopathology
- Disease Models, Animal
- Female
- Lamin Type A/genetics
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Muscle, Smooth, Vascular/metabolism
- Mutation
- Myocytes, Smooth Muscle/metabolism
- Nuclear Lamina/metabolism
- Plaque, Atherosclerotic/metabolism
- Progeria/metabolism
- Progeria/physiopathology
- Receptors, LDL/genetics
- Receptors, LDL/metabolism
Collapse
Affiliation(s)
- Rosa M. Nevado
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), 28029 Madrid, Spain; (R.M.N.); (P.G.); (M.J.A.-M.)
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain
| | - Magda R. Hamczyk
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), 28029 Madrid, Spain; (R.M.N.); (P.G.); (M.J.A.-M.)
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain
- Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, 33006 Oviedo, Spain;
| | - Pilar Gonzalo
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), 28029 Madrid, Spain; (R.M.N.); (P.G.); (M.J.A.-M.)
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain
| | - María Jesús Andrés-Manzano
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), 28029 Madrid, Spain; (R.M.N.); (P.G.); (M.J.A.-M.)
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain
| | - Vicente Andrés
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), 28029 Madrid, Spain; (R.M.N.); (P.G.); (M.J.A.-M.)
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain
- Correspondence: ; Tel.: +34-91-453-1200
| |
Collapse
|
7
|
Abstract
Lamin A, a product of the LMNA gene, is an essential nuclear envelope component in most differentiated cells. Mutations in LMNA have been linked to premature aging disorders, including Hutchinson-Gilford progeria syndrome (HGPS). HGPS is caused by progerin, an aberrant form of lamin A that leads to premature death, typically from the complications of atherosclerotic disease. A key characteristic of HGPS is a severe loss of vascular smooth muscle cells (VSMCs) in the arteries. Various mouse models of HGPS have been created, but few of them feature VSMC depletion and none develops atherosclerosis, the death-causing symptom of the disease in humans. We recently generated a mouse model that recapitulates most features of HGPS, including VSMC loss and accelerated atherosclerosis. Furthermore, by generating cell-type–specific HGPS mouse models, we have demonstrated a central role of VSMC loss in progerin-induced atherosclerosis and premature death.
Collapse
Affiliation(s)
- Magda R Hamczyk
- a Laboratory of Molecular and Genetic Cardiovascular Pathophysiology, Vascular Pathophysiology Area , Centro Nacional de Investigaciones Cardiovasculares (CNIC) , Madrid , Spain.,b CIBER de Enfermedades Cardiovasculares (CIBERCV) , Spain.,c Departamento de Bioquímica y Biología Molecular , Universidad de Oviedo , Oviedo , Spain
| | - Vicente Andrés
- a Laboratory of Molecular and Genetic Cardiovascular Pathophysiology, Vascular Pathophysiology Area , Centro Nacional de Investigaciones Cardiovasculares (CNIC) , Madrid , Spain.,b CIBER de Enfermedades Cardiovasculares (CIBERCV) , Spain
| |
Collapse
|
8
|
Hamczyk MR, Villa-Bellosta R, Quesada V, Gonzalo P, Vidak S, Nevado RM, Andrés-Manzano MJ, Misteli T, López-Otín C, Andrés V. Progerin accelerates atherosclerosis by inducing endoplasmic reticulum stress in vascular smooth muscle cells. EMBO Mol Med 2020; 11:emmm.201809736. [PMID: 30862662 PMCID: PMC6460349 DOI: 10.15252/emmm.201809736] [Citation(s) in RCA: 66] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Hutchinson–Gilford progeria syndrome (HGPS) is a rare genetic disorder caused by progerin, a mutant lamin A variant. HGPS patients display accelerated aging and die prematurely, typically from atherosclerosis complications. Recently, we demonstrated that progerin‐driven vascular smooth muscle cell (VSMC) loss accelerates atherosclerosis leading to premature death in apolipoprotein E‐deficient mice. However, the molecular mechanism underlying this process remains unknown. Using a transcriptomic approach, we identify here endoplasmic reticulum stress (ER) and the unfolded protein responses as drivers of VSMC death in two mouse models of HGPS exhibiting ubiquitous and VSMC‐specific progerin expression. This stress pathway was also activated in HGPS patient‐derived cells. Targeting ER stress response with a chemical chaperone delayed medial VSMC loss and inhibited atherosclerosis in both progeria models, and extended lifespan in the VSMC‐specific model. Our results identify a mechanism underlying cardiovascular disease in HGPS that could be targeted in patients. Moreover, these findings may help to understand other vascular diseases associated with VSMC death, and provide insight into aging‐dependent vascular damage related to accumulation of unprocessed toxic forms of lamin A.
Collapse
Affiliation(s)
- Magda R Hamczyk
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain.,Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Oviedo, Spain
| | - Ricardo Villa-Bellosta
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.,Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz (FIIS-FJD), Madrid, Spain
| | - Víctor Quesada
- Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Oviedo, Spain.,Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain
| | - Pilar Gonzalo
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain
| | - Sandra Vidak
- Cell Biology of Genomes Group, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Rosa M Nevado
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain
| | - María J Andrés-Manzano
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain
| | - Tom Misteli
- Cell Biology of Genomes Group, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Carlos López-Otín
- Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Oviedo, Spain .,Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain
| | - Vicente Andrés
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain .,Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain
| |
Collapse
|
9
|
Affiliation(s)
- Magda R Hamczyk
- Departamento de Bioquímica y Biología Molecular, Universidad de Oviedo, Oviedo, Spain
| | | |
Collapse
|
10
|
Affiliation(s)
- Magda R Hamczyk
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
| | - Vicente Andrés
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
| |
Collapse
|
11
|
Del Campo L, Hamczyk MR, Andrés V, Martínez-González J, Rodríguez C. Mechanisms of vascular aging: What can we learn from Hutchinson-Gilford progeria syndrome? Clin Investig Arterioscler 2018; 30:120-132. [PMID: 29602596 DOI: 10.1016/j.arteri.2017.12.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/21/2017] [Revised: 12/21/2017] [Accepted: 12/22/2017] [Indexed: 01/07/2023]
Abstract
Aging is the main risk factor for cardiovascular disease (CVD). The increased prevalence of CVD is partly due to the global increase in life expectancy. In this context, it is essential to identify the mechanisms by which aging induces CVD, with the ultimate aim of reducing its incidence. Both atherosclerosis and heart failure significantly contribute to age-associated CVD morbidity and mortality. Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder caused by the synthesis of progerin, which is noted for accelerated aging and CVD. This mutant form of prelamin A induces generalised atherosclerosis, vascular calcification, and cardiac electrophysiological abnormalities, leading to premature aging and death, mainly due to myocardial infarction and stroke. This review discusses the main vascular structural and functional abnormalities during physiological and premature aging, as well as the mechanisms involved in the exacerbated CVD and accelerated aging induced by the accumulation of progerin and prelamin A. Both proteins are expressed in non-HGPS individuals, and physiological aging shares many features of progeria. Research into HGPS could therefore shed light on novel mechanisms involved in the physiological aging of the cardiovascular system.
Collapse
Affiliation(s)
- Lara Del Campo
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, España; CIBER de Enfermedades Cardiovasculares (CIBERCV), España
| | - Magda R Hamczyk
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, España; CIBER de Enfermedades Cardiovasculares (CIBERCV), España
| | - Vicente Andrés
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, España; CIBER de Enfermedades Cardiovasculares (CIBERCV), España.
| | - José Martínez-González
- CIBER de Enfermedades Cardiovasculares (CIBERCV), España; Instituto de Investigaciones Biomédicas de Barcelona (IIBB-CSIC), IIB-Sant Pau, Barcelona, España
| | - Cristina Rodríguez
- CIBER de Enfermedades Cardiovasculares (CIBERCV), España; Institut de Recerca del Hospital de la Santa Creu i Sant Pau-Programa ICCC, IIB-Sant Pau, Barcelona, España.
| | | |
Collapse
|
12
|
Hamczyk MR, Villa-Bellosta R, Gonzalo P, Andrés-Manzano MJ, Nogales P, Bentzon JF, López-Otín C, Andrés V. Vascular Smooth Muscle-Specific Progerin Expression Accelerates Atherosclerosis and Death in a Mouse Model of Hutchinson-Gilford Progeria Syndrome. Circulation 2018; 138:266-282. [PMID: 29490993 PMCID: PMC6075893 DOI: 10.1161/circulationaha.117.030856] [Citation(s) in RCA: 79] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/01/2017] [Accepted: 02/15/2018] [Indexed: 01/21/2023]
Abstract
Supplemental Digital Content is available in the text. Background: Progerin, an aberrant protein that accumulates with age, causes the rare genetic disease Hutchinson-Gilford progeria syndrome (HGPS). Patients who have HGPS exhibit ubiquitous progerin expression, accelerated aging and atherosclerosis, and die in their early teens, mainly of myocardial infarction or stroke. The mechanisms underlying progerin-induced atherosclerosis remain unexplored, in part, because of the lack of appropriate animal models. Methods: We generated an atherosclerosis-prone model of HGPS by crossing apolipoprotein E–deficient (Apoe–/–) mice with LmnaG609G/G609G mice ubiquitously expressing progerin. To induce progerin expression specifically in macrophages or vascular smooth muscle cells (VSMCs), we crossed Apoe–/–LmnaLCS/LCS mice with LysMCre and SM22αCre mice, respectively. Progerin expression was evaluated by polymerase chain reaction and immunofluorescence. Cardiovascular alterations were determined by immunofluorescence and histology in male mice fed normal chow or a high-fat diet. In vivo low-density lipoprotein retention was assessed by intravenous injection of fluorescently labeled human low-density lipoprotein. Cardiac electric defects were evaluated by electrocardiography. Results: Apoe–/–LmnaG609G/G609G mice with ubiquitous progerin expression exhibited a premature aging phenotype that included failure to thrive and shortened survival. In addition, high-fat diet–fed Apoe–/–LmnaG609G/G609G mice developed a severe vascular pathology, including medial VSMC loss and lipid retention, adventitial fibrosis, and accelerated atherosclerosis, thus resembling most aspects of cardiovascular disease observed in patients with HGPS. The same vascular alterations were also observed in Apoe–/–LmnaLCS/LCSSM22αCre mice expressing progerin specifically in VSMCs, but not in Apoe–/–LmnaLCS/LCSLysMCre mice with macrophage-specific progerin expression. Moreover, Apoe–/–LmnaLCS/LCSSM22αCre mice had a shortened lifespan despite the lack of any overt aging phenotype. Aortas of ubiquitously and VSMC-specific progerin-expressing mice exhibited increased retention of fluorescently labeled human low-density lipoprotein, and atheromata in both models showed vulnerable plaque features. Immunohistopathological examination indicated that Apoe–/–LmnaLCS/LCSSM22αCre mice, unlike Apoe–/–LmnaG609G/G609G mice, die of atherosclerosis-related causes. Conclusions: We have generated the first mouse model of progerin-induced atherosclerosis acceleration, and demonstrate that restricting progerin expression to VSMCs is sufficient to accelerate atherosclerosis, trigger plaque vulnerability, and reduce lifespan. Our results identify progerin-induced VSMC death as a major factor triggering atherosclerosis and premature death in HGPS.
Collapse
Affiliation(s)
- Magda R Hamczyk
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain (M.R.H., R.V.-B., P.G., M.J.A.-M., P.N., J.F.B., V.A.)
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain (M.R.H., M.J.A.-M., V.A.)
| | - Ricardo Villa-Bellosta
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain (M.R.H., R.V.-B., P.G., M.J.A.-M., P.N., J.F.B., V.A.)
| | - Pilar Gonzalo
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain (M.R.H., R.V.-B., P.G., M.J.A.-M., P.N., J.F.B., V.A.)
| | - María J Andrés-Manzano
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain (M.R.H., R.V.-B., P.G., M.J.A.-M., P.N., J.F.B., V.A.)
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain (M.R.H., M.J.A.-M., V.A.)
| | - Paula Nogales
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain (M.R.H., R.V.-B., P.G., M.J.A.-M., P.N., J.F.B., V.A.)
| | - Jacob F Bentzon
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain (M.R.H., R.V.-B., P.G., M.J.A.-M., P.N., J.F.B., V.A.)
- Department of Clinical Medicine, Aarhus University, Denmark (J.F.B.)
| | - Carlos López-Otín
- Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Spain (C.L.-O.)
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain (C.L.-O.). The present affiliation for Dr Villa-Bellosta is Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz (FIIS-FJD), Madrid, Spain
| | - Vicente Andrés
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain (M.R.H., R.V.-B., P.G., M.J.A.-M., P.N., J.F.B., V.A.).
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain (M.R.H., M.J.A.-M., V.A.)
| |
Collapse
|
13
|
Abstract
Aging, the main risk factor for cardiovascular disease (CVD), is becoming progressively more prevalent in our societies. A better understanding of how aging promotes CVD is therefore urgently needed to develop new strategies to reduce disease burden. Atherosclerosis and heart failure contribute significantly to age-associated CVD-related morbimortality. CVD and aging are both accelerated in patients suffering from Hutchinson-Gilford progeria syndrome (HGPS), a rare genetic disorder caused by the prelamin A mutant progerin. Progerin causes extensive atherosclerosis and cardiac electrophysiological alterations that invariably lead to premature aging and death. This review summarizes the main structural and functional alterations to the cardiovascular system during physiological and premature aging and discusses the mechanisms underlying exaggerated CVD and aging induced by prelamin A and progerin. Because both proteins are expressed in normally aging non-HGPS individuals, and most hallmarks of normal aging occur in progeria, research on HGPS can identify mechanisms underlying physiological aging.
Collapse
Affiliation(s)
- Magda R Hamczyk
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), 28029 Madrid, Spain; .,CIBER de Enfermedades Cardiovasculares (CIBER-CV), 28029 Madrid, Spain
| | - Lara del Campo
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), 28029 Madrid, Spain; .,CIBER de Enfermedades Cardiovasculares (CIBER-CV), 28029 Madrid, Spain
| | - Vicente Andrés
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), 28029 Madrid, Spain; .,CIBER de Enfermedades Cardiovasculares (CIBER-CV), 28029 Madrid, Spain
| |
Collapse
|
14
|
Villa-Bellosta R, Hamczyk MR, Andrés V. Novel phosphate-activated macrophages prevent ectopic calcification by increasing extracellular ATP and pyrophosphate. PLoS One 2017; 12:e0174998. [PMID: 28362852 PMCID: PMC5376322 DOI: 10.1371/journal.pone.0174998] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2016] [Accepted: 03/17/2017] [Indexed: 12/17/2022] Open
Abstract
PURPOSE Phosphorus is an essential nutrient involved in many pathobiological processes. Less than 1% of phosphorus is found in extracellular fluids as inorganic phosphate ion (Pi) in solution. High serum Pi level promotes ectopic calcification in many tissues, including blood vessels. Here, we studied the effect of elevated Pi concentration on macrophage polarization and calcification. Macrophages, present in virtually all tissues, play key roles in health and disease and display remarkable plasticity, being able to change their physiology in response to environmental cues. METHODS AND RESULTS High-throughput transcriptomic analysis and functional studies demonstrated that Pi induces unpolarized macrophages to adopt a phenotype closely resembling that of alternatively-activated M2 macrophages, as revealed by arginine hydrolysis and energetic and antioxidant profiles. Pi-induced macrophages showed an anti-calcifying action mediated by increased availability of extracellular ATP and pyrophosphate. CONCLUSION We conclude that the ability of Pi-activated macrophages to prevent calcium-phosphate deposition is a compensatory mechanism protecting tissues from hyperphosphatemia-induced pathologic calcification.
Collapse
Affiliation(s)
- Ricardo Villa-Bellosta
- Centro Nacional de Investigaciones CardiovascularesCarlos III (CNIC), Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
- Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz (FIIS-FJD), Madrid, Spain
| | - Magda R. Hamczyk
- Centro Nacional de Investigaciones CardiovascularesCarlos III (CNIC), Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
| | - Vicente Andrés
- Centro Nacional de Investigaciones CardiovascularesCarlos III (CNIC), Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
| |
Collapse
|
15
|
Villa-Bellosta R, Hamczyk MR, Andrés V. Alternatively activated macrophages exhibit an anticalcifying activity dependent on extracellular ATP/pyrophosphate metabolism. Am J Physiol Cell Physiol 2016; 310:C788-99. [PMID: 26936458 DOI: 10.1152/ajpcell.00370.2015] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2015] [Accepted: 02/25/2016] [Indexed: 11/22/2022]
Abstract
Calcium-phosphate deposition (CPD) in atherosclerotic lesions, which begins in middle age and increases with aging, is a major independent predictor of future cardiovascular disease morbi-mortality. Remodeling of atherosclerotic vessels during aging is regulated in part by intimal macrophages, which can polarize to phenotypically distinct populations with distinct functions. This study tested the hypothesis that classically activated macrophages (M1φs) and alternatively activated macrophages (M2φs) differently affect vascular smooth muscle cell (VSMC) calcification and investigated the underlying mechanisms. We analyzed mouse VSMC-macrophage cocultures using a transwell system. Coculture of VSMCs with M2φs significantly reduced CPD, but coculture with M1φs had no effect. The anticalcific effect of M2φs was associated with elevated amounts of extracellular ATP and pyrophosphate (PPi), two potent inhibitors of CPD, and was lost upon forced hydrolysis of these metabolites. In M2φs and VSMC-M2φs cocultures, analysis of the ectoenzymes that regulate extracellular ATP/PPi metabolism revealed increased mRNA expression and activity of ectoenzyme nucleotide pyrophosphatase/phosphodiesterase-1, which synthesizes PPi from ATP, without changes in tissue-nonspecific alkaline phosphatase, which hydrolyzes PPi In conclusion, increased accumulation of extracellular ATP and PPi by alternatively activated mouse M2φs inhibits CPD. These results reveal novel mechanisms underlying macrophage-dependent control of intimal calcification.
Collapse
Affiliation(s)
| | - Magda R Hamczyk
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain
| | - Vicente Andrés
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain
| |
Collapse
|
16
|
Abstract
The key roles of macrophages in atherosclerosis include the phagocytosis of apoptotic and necrotic cells and cell debris, whose accumulation in atherosclerotic lesions exacerbates inflammation and promotes plaque vulnerability. Evidence is accumulating that macrophage phagocytic functions peak at the early stages of atherosclerosis and that the reduced phagocytosis at the late stages of disease leads to the generation of necrotic cores and a defective resolution of inflammation, which in turn promotes plaque rupture, thrombus formation, and life-threatening acute ischemic events (myocardial infarction and stroke). The impaired resolution of inflammation in advanced lesions featuring loss of macrophage phagocytic activity may be in part due to an imbalance between M1 and M2 subsets of polarized macrophages. A better understanding of the mechanisms that regulate macrophage phagocytic activity in the context of atherosclerosis may therefore help identify novel therapeutic targets. This chapter presents a protocol for establishing primary mouse macrophage cultures, a method for polarizing macrophages to the M1 and M2 states, and a method for the in vitro study of macrophage phagocytosis of IgG-opsonized or IgM/complement component 3-opsonized erythrocytes.
Collapse
Affiliation(s)
- Magda R Hamczyk
- Laboratory of Molecular and Genetic Cardiovascular Pathophysiology, Vascular Biology Program, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain
| | - Ricardo Villa-Bellosta
- Laboratory of Molecular and Genetic Cardiovascular Pathophysiology, Vascular Biology Program, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain
| | - Vicente Andrés
- Laboratory of Molecular and Genetic Cardiovascular Pathophysiology, Vascular Biology Program, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
| |
Collapse
|
17
|
Abstract
Elevated serum phosphorus is a major risk factor for vascular calcification, which is characterized by the presence of calcium phosphate deposits, mainly hydroxyapatite crystals. In vitro studies of phosphate-induced calcification show that vascular smooth muscle cells undergo calcification with features similar to those observed in pathological vascular calcification in vivo, including the presence of hydroxyapatite crystals. Here, we describe the double-collagenase digestion method for isolating vascular smooth muscle cells from aorta, and a method for inducing calcification in vitro using high phosphate concentration.
Collapse
MESH Headings
- Animals
- Aorta/drug effects
- Aorta/metabolism
- Aorta/pathology
- Aortic Diseases/chemically induced
- Aortic Diseases/metabolism
- Aortic Diseases/pathology
- Calcium Phosphates/toxicity
- Cell Separation/methods
- Cells, Cultured
- Collagenases/metabolism
- Crystallization
- Durapatite/metabolism
- Mice
- Muscle, Smooth, Vascular/drug effects
- Muscle, Smooth, Vascular/metabolism
- Muscle, Smooth, Vascular/pathology
- Myocytes, Smooth Muscle/drug effects
- Myocytes, Smooth Muscle/metabolism
- Myocytes, Smooth Muscle/pathology
- Primary Cell Culture
- Vascular Calcification/chemically induced
- Vascular Calcification/metabolism
- Vascular Calcification/pathology
Collapse
Affiliation(s)
- Ricardo Villa-Bellosta
- Laboratory of Molecular and Genetic Cardiovascular Pathophysiology, Vascular Biology Program, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Melchor Fernández Almagro 3, 28029, Madrid, Spain.
| | - Magda R Hamczyk
- Laboratory of Molecular and Genetic Cardiovascular Pathophysiology, Vascular Biology Program, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Melchor Fernández Almagro 3, 28029, Madrid, Spain
| |
Collapse
|